Datasets
Biomedical and Pharma Anchors
Dated Singapore biomedical manufacturing scale, GDP contribution, plant counts, and Biopolis/Tuas anchors — distinct from clinical healthcare financing.
Biomedical and Pharma Anchors
Use each row with its as-of date. Manufacturing regulation (HSA) is distinct from clinical healthcare (MOH). Narrative lives in biomedical and pharma.
Scale and GDP contribution
| Metric | Value | Denominator / notes | As of |
|---|---|---|---|
| BMS GDP contribution | About 1.9% of GDP | Biopharmaceutical + medical technology activity | 2024 |
| Product value for global markets | More than S$32 billion | >85% increase vs two decades earlier | 2024 framing |
| Manufacturing plants | More than 60 | BMS manufacturing plants in Singapore | Accessed Aug 2026 |
| R&D centres | More than 30 | Corporate/public research centres | Accessed Aug 2026 |
| Regional headquarters | More than 80 | Including eight of top 10 biopharma firms (gov framing) | Accessed Aug 2026 |
Source: EDB biomedical powerhouse, accessed 9 August 2026.
Manufacturing cluster share (April 2026)
| Metric | Value | Notes | As of |
|---|---|---|---|
| Biomedical share of manufacturing output | 11.3% | Index basis 2025=100 | Apr 2026 |
| Pharmaceuticals share | 3.7% | Within manufacturing output index | Apr 2026 |
| Medical technology share | 7.6% | Within manufacturing output index | Apr 2026 |
| Biomedical output YoY | −16.1% | Softer devices + lower biologics | Apr 2026 |
Source: EDB Monthly Manufacturing Performance, with the April 2026 media release, accessed 14 August 2026.
Investment and campuses
| Anchor | Value | Notes | As of |
|---|---|---|---|
| Fixed-asset investments (BMS) | S$4.4 billion | Projected 1,775 jobs over five years | 2025 |
| Biopolis | Opened Oct 2003 | one-north biomedical R&D campus | 2003 |
| Tuas Biomedical Park | Manufacturing park (JTC) | Distinct from clinical hospitals | Ongoing |
Source: MTI PQ reply; EDB/NAS campus framing, accessed 9 August 2026.
Record details
- Also known as
- ["BMS manufacturing","Tuas Biomedical Park","Biopolis"]
- Jurisdiction
- SG
- What each row represents
- one dated BMS GDP/plant/VA or campus investment anchor
- Update cadence
- after EDB manufacturing stats or BMS investment announcements
- Source format
- markdown
Dates describe this record’s own period and applicability. A verification date does not mean a rule is currently in force.
Sources
- EDB — Singapore's rise as a biomedical sciences powerhouse Accessed 2026-08-09
- EDB — Monthly Manufacturing Performance Accessed 2026-08-09
- EDB — Monthly Manufacturing Performance April 2026 infographic Accessed 2026-08-14
- MTI — Written reply on biomedical sector resilience Accessed 2026-08-09
Collection as of 2026-10-07 · An expanding collection. Published counts show available knowledge, not complete coverage of Singapore.